Pneumococcal Conjugate Vaccine 13-Valent (13vpcv) And Pneumococcal Polysaccharide Vaccine 23-Valent (23vppv)
Prevention of pneumococcal disease in high-risk populations across the lifespan, including healthy adults aged ≥70 years (non-Aboriginal and Torres Strait Islander), Aboriginal and Torres Strait Islander adults aged ≥50 years, persons ≥5 years with high-risk medical conditions, and children under 5 years at very high risk of pneumococcal disease.
Access path
- Jul 2019Recommended
vs no vaccine
- PBS listing · Restricted
From the public summary
4.1 The PBAC recommended the implementation of a whole-of-life NIP-funded pneumococcal vaccine schedule, in line with ATAGI’s June 2019 advice. The PBAC 6PSD · Jul 2019
4.2 The PBAC reaffirmed its July 2016 recommendation that, on the basis of cost- effectiveness compared with 23vPPV, a single dose of 13vPCV should replace the single dose (or the first dose for those adults with risk factors) of 23vPPV that is currently provided to the older adult populations through the NIP (>65 years non- Aboriginal and Torres Strait Islander, >50 years Aboriginal and Torres Strait Islander).PSD · Jul 2019
Cost-effectiveness
Cost-effectiveness review was conducted but specific ICER values are not stated in the PSD. The document references a CER report and discusses cost-effectiveness qualitatively (e.g., 'acceptable cost-effectiveness', 'high but acceptable cost-effectiveness') without publishing numeric ICER values.
Decision context
PopulationHigh-risk populations including: healthy non-Aboriginal and Torres Strait Islander adults ≥70 years; Aboriginal and Torres Strait Islander adults ≥50 years; all persons ≥5 years newly diagnosed with conditions associated with very high risk of pneumococcal disease; non-Aboriginal and Torres Strait Islander children 2-12 months with very high risk; Aboriginal and Torres Strait Islander children <5 years in high-incidence areas (WA, QLD, SA, NT); and children 12-59 months with high-risk medical conditions.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2019 | Recommended | no vaccine | — | Cost-minimisation · Cost-minimisation |
Consumer voice
Five organisations (The Lung Foundation, Asthma Australia, National Seniors, Royal Australian College of General Practitioners, and COTA Australia) and three health professionals raised concerns about increasing the vaccination age from 65 to 75 years and replacing 23vPPV with 13vPCV, particularly for populations with chronic lung diseases. Seqirus (sponsor of 23vPPV) supported these concerns and
the large population aged between 65 and 75 years that would have increased risk of exposure to pneumococcal pneumonia Consumer comments · PSD